afuresertib
Small moleculeexperimental
Clinical trial activity
20 trials · 14 clinical orgs · 0 marketing orgs
Phase 1
15
Phase 2
10
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2009 (NCT00881946)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Healthy Volunteers · Phase 1
- Hematologic Neoplasms · Phase 1/Phase 2
- Histiocytosis, Langerhans-Cell · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Multiple Myeloma · Phase 1
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1/Phase 2
Mechanism of action
- Serine/threonine-protein kinase AKTINHIBITOR
Serine/threonine-protein kinase AKT inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl- Mol. weight
- 427.33 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2219422 ↗
Also known as
- afuresertib
- afuresertib
- afuresertib
- afuresertib
- gsk2110183
- gsk2110183
- gsk2110183
- gsk2110183c
- gsk2110183c
- gsk21110183
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05489744 | Phase 1 | Jul 28, 2022 | Laekna Limited, Soochow University |
| NCT05383482 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2022 | Chinese Academy of Medical Sciences, Laekna Limited |
| NCT04851613 | Phase 1 | Sep 30, 2021 | Laekna Limited |
| NCT05390710 | Phase 1/Phase 2 (Phase 2) | Jun 12, 2021 | Chinese Academy of Medical Sciences, Laekna Limited |
| NCT04374630 | Phase 2 | Jun 9, 2020 | Laekna Limited |
| NCT04060394 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2019 | Laekna Limited |
| NCT02380313 | Phase 1 | Oct 1, 2015 | GlaxoSmithKline |
| NCT02235740 | Phase 1 | Nov 1, 2014 | Amgen, Novartis |
| NCT02240212 | Phase 1 | Oct 1, 2014 | Novartis |
| NCT02177682 | Phase 1 | Aug 13, 2014 | Novartis |
| NCT02040480 | Phase 1 | Feb 1, 2014 | GlaxoSmithKline |
| NCT01827644 | Phase 1 | Apr 1, 2013 | GlaxoSmithKline |
| NCT01653912 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2012 | Accenture, GlaxoSmithKline, INC Research, Peter MacCallum Cancer Centre, University of Edinburgh, University of London, University of Melbourne, University of Western Australia |
| NCT01531894 | Phase 2 | Feb 8, 2012 | Novartis |
| NCT01532700 | Phase 2 | Feb 1, 2012 | Novartis, University of Toronto |
| NCT01428492 | Phase 1 | Dec 1, 2011 | Novartis |
| NCT01395004 | Phase 2 | Nov 1, 2011 | Accenture |
| NCT01445587 | Phase 2 | Nov 1, 2011 | GlaxoSmithKline |
| NCT01476137 | Phase 1 | Oct 1, 2011 | GlaxoSmithKline |
| NCT00881946 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2009 | Accenture |
Showing 20 of 20 trials
Page 1 / 1
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 6 | 5 | 2 | 2011 |
| Laekna Limited | For profit | 6 | 6 | 2 | 2019 |
| Novartis | For profit | 6 | 5 | 2 | 2011 |
| Accenture | For profit | 3 | 3 | 1 | 2009 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 1 | 2021 |
| Amgen | For profit | 1 | 0 | 1 | 2014 |
| INC Research | For profit | 1 | 0 | 1 | 2012 |
| Peter MacCallum Cancer Centre | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Soochow University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Edinburgh | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Melbourne | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University of Western Australia | Academic/Hospital | 1 | 0 | 1 | 2012 |
14 organizations
Page 1 / 1